PAX5 and lymphoma: This double staining was so far reported in Kiyasu’s study of 1091 patients with DLBCL14, NOS and Chen’s study of various lymphoma subtypes, including 66 patients with DLBCL, NOS33, but both studies used only PD-L1/PAX5 staining.